pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 9·1 min read
save

Podcast discusses health insurance costs, whistleblower case, and potential FDA commissioner picks

Jul 9, 2026·read at STAT ↗RegulatoryNeutral

The Readout LOUD podcast episode explores why employer-provided family health insurance can be as expensive as a new car.

The hosts interview a whistleblower who challenged an insurance contractor over cost practices, highlighting concerns about transparency and pricing.

They also discuss the pool of candidates being considered for the next FDA commissioner, noting how leadership choices could affect upcoming regulatory policies.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Whistleblower takes on health insurance and FDA commissioner candidates”

read at STAT ↗
644 words · retrieved Jul 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA2ELI LILLY COLILLY
drugs
Obesity4
topics
Obesity4Oncology

related stories

  • 1d agoPharma’s $500B patent problem will come in waves — not as a cliffBioPharma Dive
  • Oct 75 biggest venture capital raises of Q3 2026BioSpace
  • Oct 6The top biopharma conferences in 2027BioPharma Dive
  • Sep 14STAT+: What’s in a name? Novo looks to a rebrandSTAT
  • Sep 4This week in charts: China deals, stock flatlines and Lilly’s M&A spreeBioPharma Dive